Sei Investments Co. Purchases 3,844 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Sei Investments Co. grew its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 86,503 shares of the medical research company's stock after purchasing an additional 3,844 shares during the quarter. Sei Investments Co.'s holdings in IQVIA were worth $16,999,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Raymond James Financial Inc. bought a new position in IQVIA during the 4th quarter valued at $236,120,000. American Century Companies Inc. lifted its position in shares of IQVIA by 396.0% during the fourth quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock valued at $222,987,000 after purchasing an additional 905,960 shares in the last quarter. FMR LLC boosted its holdings in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock worth $684,213,000 after purchasing an additional 804,963 shares during the last quarter. JPMorgan Chase & Co. grew its position in IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Finally, Nordea Investment Management AB increased its stake in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock valued at $277,908,000 after buying an additional 452,029 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on IQV shares. Stephens began coverage on IQVIA in a research note on Friday, December 20th. They issued an "overweight" rating and a $250.00 target price on the stock. StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. UBS Group decreased their target price on IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Stifel Nicolaus cut their price target on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Finally, BTIG Research cut shares of IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $249.05.

IQVIA Price Performance

Shares of IQVIA stock traded down $2.03 on Tuesday, reaching $174.28. The stock had a trading volume of 147,787 shares, compared to its average volume of 1,298,551. The business's 50 day moving average is $192.73 and its two-hundred day moving average is $205.61. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 1 year low of $169.37 and a 1 year high of $253.84. The company has a market cap of $30.73 billion, a P/E ratio of 23.17, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.